Physician profile
Nathan D Wass
NPI 1568725190
$1,034.52
in general payments reported to CMS, 2019-2025
18 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $55.28 · 2021: $28.60 · 2022: $46.00 · 2023: $132 · 2024: $52.34 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.10 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $348.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $109.86 | 2019-2025 | |
| Amgen INC. | $98.87 | 2019-2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $65.74 | 2019 | |
| Antares Pharma, INC. | $56.91 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.40 | 2019-2025 | Jardiance |
| Abbvie INC. | $48.62 | 2025 | |
| Merck Sharp & Dohme LLC | $41.78 | 2019-2023 | M-M-R II, Gardasil 9 |
| Corium, LLC | $33.63 | 2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $30.99 | 2025 | Breztri, Airsupra |
| Allergan, INC. | $28.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.55 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.94 | 2019 | |
| Glaxosmithkline, LLC. | $18.68 | 2024 | Trelegy Ellipta |
| Lilly USA, LLC | $15.53 | 2025 | Mounjaro, Zepbound |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.63 | 2020 | |
| Sumitomo Pharma America, INC. | $13.35 | 2024 | Gemtesa |
| Shire North American Group INC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Wass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.